ClinicalTrials.gg
Not yet recruitingNCT07887750Updated Oct 21, 2026

REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)

A Phase 1/2 interventional study of REGN9220 and Odronextamab in Diffuse Large B-Cell Lymphoma (DLBCL), sponsored by Regeneron Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Updated Oct 21, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Lymphoma, Large B-Cell, Diffuse by Regeneron Pharmaceuticals — 2 open to participants now, 3 under way, 1 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Regeneron Pharmaceuticals.

Started
2026
the only one that year
Phase 1/2
Only one
of the 12
Registered
12th of 12
by date

Among the 12 studies in Lymphoma, Large B-Cell, Diffuse by Regeneron Pharmaceuticals, this one is the only one that started in 2026, is the only one in phase 1/2, and was the 12th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

2 of the 12 studies in Lymphoma, Large B-Cell, Diffuse by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lymphoma, Large B-Cell, Diffuse by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This study will test a new experimental study drug called REGN9220 with a Regeneron drug called odronextamab (both called "study drug") to see if it can help treat people with aggressive BCNHL that has either come back/gotten worse or has not responded to previous treatment.

The study is looking at:

  • What side effects REGN9220 might cause when given with odronextamab
  • How well REGN9220 works when given with odronextamab
  • How much REGN9220 is in the blood at different times when given with odronextamab
  • If the body makes antibodies to REGN9220 when given with odronextamab, this may cause the REGN9220 to not work as well
  • How the body and immune system changes after having REGN9220 given with odronextamab, which can help researchers understand why REGN9220 given with odronextamab works better in some people than others
  • What is the best dose of REGN9220 when given with odronextamab
03

Conditions studied

  • Diffuse Large B-Cell Lymphoma (DLBCL)

Keywords

  • Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Documented Cluster of Differentiation (CD)20+ aggressive B-cell non-Hodgkin lymphoma that is
  2. on cross sectional imaging
  3. (ECOG) performance status 0-1
  4. Adequate organ function (hematologic, hepatic, and renal)
  5. Availability of tumor tissue for analysis for submission to central laboratory is required for trial enrollment
  6. Willingness to comply with requirements and study procedures

Key Exclusion Criteria:

  1. Diagnosis of Mantle Cell Lymphoma (MCL) or Central Nervous System (CNS) lymphoma
  2. Significant CNS disorders
  3. Active/uncontrolled infections
  4. Prior treatment with anti-CD20 x anti-CD3 bispecific antibody
  5. Recent cancer therapy or major surgery
  6. Drug
  7. Significant comorbidities
  8. Pregnancy/breastfeeding

NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    REGN9220 + Odronextamab

    Drug: REGN9220 · Drug: Odronextamab

Interventions

  • DrugREGN9220

    Administered per the protocol

  • Administered per the protocol

    Also known as: REGN1979, Ordspono™

06

What researchers measure

Primary outcomes

  1. Occurrence of Dose-Limiting Toxicities (DLTs) during the DLT observation period

    Time frame: Up to 28 days

  2. Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 2 years

  3. Severity of TEAEs

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Concentration of REGN9220 in serum when given in combination with odronextamab

    Time frame: Up to approximately 2 years

  2. Concentration of odronextamab in serum when given in combination with REGN9220

    Time frame: Up to approximately 2 years

  3. Occurrence of Anti-Drug Antibodies (ADA) to REGN9220

    Time frame: Up to approximately 2 years

  4. Magnitude of ADA to REGN9220

    Time frame: Up to approximately 2 years

  5. Occurrence of ADA to odronextamab

    Time frame: Up to approximately 2 years

  6. Magnitude of ADA to odronextamab

    Time frame: Up to approximately 2 years

  7. Best Overall Response (BOR)

    Time frame: Up to 90 days post last study drug administration

  8. Complete Response (CR)

    Time frame: Up to 90 days post last study drug administration

  9. Progression-Free Survival (PFS)

    Time frame: Up to 90 days post last study drug administration

  10. Duration Of Response (DOR)

    Time frame: Up to 90 days post last study drug administration

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Nov 2029, 34 months later.

Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's planned 34 months is below that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Oct 21, 2026
StartEst.
Dec 7, 2026
Primary completionEst.
Nov 1, 2029
CompletionEst.
Nov 1, 2029
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07887750
Responsible party
Sponsor
First posted
Oct 21, 2026
Start date
Dec 7, 2026 (estimated)
Primary completion
Nov 1, 2029 (estimated)
Completion
Nov 1, 2029 (estimated)
Last update
Oct 21, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion